London: British drug giant AstraZeneca has paused a planned £200 million expansion of its research site in Cambridge, the company said. This decision follows the pharmaceutical firm's abandonment of plans to invest £450 million in a vaccine plant in Merseyside earlier this year, posing a challenge to the government's efforts to emphasize its commitment to economic growth and attract international investors.
According to Emirates News Agency, an AstraZeneca spokesperson stated on Friday, "We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused. We have no further comment to make." This move underscores AstraZeneca's evolving investment strategy, as it balances global opportunities against economic viability.
In February, AstraZeneca Chief Executive Pascal Soriot expressed disappointment over the cancellation of the Merseyside site, stating that the investment could not be economically justified. This reflects the complex decision-making processes pharmaceutical companies face when evaluating large-scale investments.
Last month, AstraZeneca announced significant plans to invest $50 billion in the United States over the next five years. This investment is aimed at establishing a new manufacturing facility in Virginia, expected to be the company's largest single manufacturing investment globally. Additionally, the firm plans to enhance research and development, along with cell therapy manufacturing, in multiple US states, including Maryland, Massachusetts, California, Indiana, and Texas.